ES2544808T3 - Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas - Google Patents

Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas Download PDF

Info

Publication number
ES2544808T3
ES2544808T3 ES11157947.0T ES11157947T ES2544808T3 ES 2544808 T3 ES2544808 T3 ES 2544808T3 ES 11157947 T ES11157947 T ES 11157947T ES 2544808 T3 ES2544808 T3 ES 2544808T3
Authority
ES
Spain
Prior art keywords
lta
prophylaxis
gram
therapy
vaccine component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11157947.0T
Other languages
English (en)
Inventor
Johannes Huebner
Andrea Kropec-Huebner
Gijsbert Arie Van Der Marel
Wouter Frederik Johan HOGENDORF
Jeroen Dirk Cornelis CODÉE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsklinikum Freiburg
Universiteit Leiden
Original Assignee
Universitaetsklinikum Freiburg
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Freiburg, Universiteit Leiden filed Critical Universitaetsklinikum Freiburg
Application granted granted Critical
Publication of ES2544808T3 publication Critical patent/ES2544808T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un mimético sintético de ácido lipoteicoico (LTA) que tiene la siguiente fórmula general (III)**Fórmula** en donde z es un número entero seleccionado de 1 a 40, y preferiblemente seleccionado de 4 a 6, en donde R1 se selecciona de H o un resto carbohidrato, y L es un resto enlazador para conectar dicho mimético a una proteína de soporte adecuada, o sales o solvatos del mismo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
E11157947
06-08-2015
J. Huebner, Y. Wang, W. A. Krueger, L. C. Madoff, G. Martirosian, S. Boisot, D. A. Goldmann, D. L. Kasper, A. O. Tzianabos y G. B. Pier (1999). "Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium." Infect Immun 67(3): 1213-1219.
5 J. Huebner, A. Quaas, W. A. Krueger, D. A. Goldmann y G. B. Pier (2000). "Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant enterococci." Infect Immun 68(8): 4631-4636.
C. Theilacker, Z. Kaczynski, A. Kropec, F. Fabretti, T. Sange, O. Holst y J. Huebner (2006). "Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid." Infect Immun 74(10): 5703-5712.
10 I. G. Sava, E. Heikens y J. Huebner (2010). "Pathogenesis and immunity in enterococcal infections." Clin Microbiol Infect 16(6): 533-540.
W. F. Hogendorf, L. J. Bos, H. S. Overkleeft, J. D. Codee y G. A. Marel (2010). "Synthesis of an alpha-kojibiosyl substituted glycerol teichoic acid hexamer." Bioorg Med Chem 18(11): 3668-3678.
9

Claims (1)

  1. imagen1
    imagen2
ES11157947.0T 2011-03-11 2011-03-11 Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas Active ES2544808T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20110157947 EP2500349B1 (en) 2011-03-11 2011-03-11 Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections

Publications (1)

Publication Number Publication Date
ES2544808T3 true ES2544808T3 (es) 2015-09-04

Family

ID=43828266

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11157947.0T Active ES2544808T3 (es) 2011-03-11 2011-03-11 Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas

Country Status (7)

Country Link
US (1) US9290531B2 (es)
EP (1) EP2500349B1 (es)
JP (1) JP6154751B2 (es)
CA (1) CA2829126A1 (es)
ES (1) ES2544808T3 (es)
HK (1) HK1175786A1 (es)
WO (1) WO2012119846A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780351B1 (en) * 2011-11-18 2019-12-18 National Research Council of Canada (NRC) Clostridium difficile lipoteichoic acid and uses thereof
WO2018013999A1 (en) 2016-07-15 2018-01-18 Am Chemicals Llc Non-nucleosidic solid supports and phosphoramidite building blocks for oligonucleotide synthesis
KR101950881B1 (ko) * 2017-08-10 2019-02-22 서울대학교산학협력단 리포테이코익산(Lipoteichoic acid(LTA))을 함유하는 피부 재생 및 창상 치유용 약학 조성물
BR112020004471A8 (pt) * 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023896A1 (en) * 1995-01-30 1996-08-08 Peter Truog Antitumor and anticholesterol preparations containing a lipoteichoic acid from steptococcus
AUPQ137699A0 (en) 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
CA2474709A1 (en) * 2002-02-04 2003-08-14 Biomira, Inc. Immunostimulatory, covalently lipidated oligonucleotides

Also Published As

Publication number Publication date
EP2500349A1 (en) 2012-09-19
JP2014507450A (ja) 2014-03-27
WO2012119846A1 (en) 2012-09-13
US20140050741A1 (en) 2014-02-20
EP2500349B1 (en) 2015-05-06
HK1175786A1 (en) 2013-07-12
JP6154751B2 (ja) 2017-06-28
CA2829126A1 (en) 2012-09-13
US9290531B2 (en) 2016-03-22

Similar Documents

Publication Publication Date Title
ES2544808T3 (es) Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas
AR076753A1 (es) Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides.
RU2017123262A (ru) Иммуногенные композиции для применения в пневмококковых вакцинах
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
DOP2009000124A (es) Derivados de benzamida como receptores agonista ep4
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
CY1118288T1 (el) Διαδικασια παρασκευης οιστετρολης
Wahid et al. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
DOP2010000387A (es) Compuestos pirazolicos 436
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
AR078522A1 (es) Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CO6390101A2 (es) Compuestos purina
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
DOP2012000312A (es) Triazolopiridinas sustituidas
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
MX2011012934A (es) Lipopolisacarido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos.
CU20120083A7 (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificación para el uso como principio activo farmacéutico
IL273685B2 (en) Immunogens and vaccines containing O25b antigens
BR112016012306A2 (pt) peptídeos ricos em prolina para proteção contra s. pneumoniae
ES2640752T3 (es) Agonistas del receptor 5-HT4 para el tratamiento de la demencia